Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Trop Med Int Health. 2014 Feb;19(2):177-85. doi: 10.1111/tmi.12233. Epub 2013 Dec 9.
Worldwide, rotavirus infections cause approximately 453,000 child deaths annually. Two licensed vaccines could be life- and cost-saving in low-income countries where the disease burden is highest. The aim of our study was to estimate the total cost of implementing the rotavirus vaccine in the national immunisation programme of a low-income country. Furthermore, the aim was to examine the relative contribution of different components to the total cost.
Following the World Health Organization guidelines, we estimated the resource use and costs associated with rotavirus vaccine implementation, using Malawi as a case. The cost analysis was undertaken from a governmental perspective. All costs were calculated for a 5-years period (2012-2016) and discounted at 5%. The value of key input parameters was varied in a sensitivity analysis.
The total cost of rotavirus vaccine implementation in Malawi amounted to US$ 18.5 million over a 5-years period. This translated into US$ 5.8 per child in the birth cohort. With GAVI Alliance financial support, the total cost was reduced to US$ 1.4 per child in the birth cohort. Approximately 83% of the total cost was attributed to vaccine purchase, while 17% was attributed to system costs, with personnel, transportation and cold chain as the main cost components.
The total cost of rotavirus vaccine implementation in Malawi is high compared with the governmental health budget of US$ 26 per capita per year. This highlights the need for new financing opportunities for low-income countries to facilitate vaccine implementation and ensure sustainable financing.
在全球范围内,轮状病毒感染每年导致约 45.3 万名儿童死亡。在疾病负担最高的低收入国家,两种已获许可的疫苗可以挽救生命和节省成本。我们研究的目的是估计在低收入国家的国家免疫规划中实施轮状病毒疫苗的总成本。此外,目的是研究不同组成部分对总成本的相对贡献。
我们按照世界卫生组织的指导方针,以马拉维为例,估算了与轮状病毒疫苗实施相关的资源利用和成本。成本分析是从政府角度进行的。所有成本均在 5 年期间(2012-2016 年)进行计算,并贴现 5%。在敏感性分析中,对关键输入参数的价值进行了调整。
在马拉维实施轮状病毒疫苗的总成本在 5 年内达到 1850 万美元。这相当于出生队列中每个儿童 5.8 美元。在全球疫苗免疫联盟财政支持下,出生队列中每个儿童的总成本降至 1.4 美元。总成本的约 83%归因于疫苗采购,而 17%归因于系统成本,人员、运输和冷链是主要成本组成部分。
与马拉维政府每年人均 26 美元的卫生预算相比,实施轮状病毒疫苗的总成本很高。这突出表明,低收入国家需要新的融资机会来促进疫苗的实施并确保可持续融资。